In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that...

|About: Celgene Corporation (CELG)|By:, SA News Editor

In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that its Abraxane treatment for advanced pancreatic cancer lengthened the survival of patients in a Phase III study. Pancreatic cancer could add up to $1B in sales of Abraxane, which is already approved to treat breast and lung tumors.